FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2394874480> ?p ?o ?g. }

• W2394874480 endingPage "97" @default.
• W2394874480 startingPage "385" @default.
• W2394874480 abstract "Sera from clinically immune individuals comprising 10 hospitalised patients (Group I), 30 persons residing in a malaria endemic area in Thailand (Group II) and 8 persons from a hyperendemic area in Ivory Coast (Group III) were tested by the parasite growth inhibition (PGI), indirect fluorescent antibody test of ring-infected erythrocyte surface antigen (RESA-IFA), urease-ELISA and Western blot. Paired sera from patients recovering from malaria (Group IV) as well as sera from blood donors were also tested. In the PGI test, sera were tested against three uncloned isolates of P. falciparum comprising SO, I4 and AE9 (PGI-SO, PGI-I4 and PGI-AE9 respectively). When growth inhibition of greater than or equal to 30% against any one of the three isolates was considered positive, the positive rate for the combined Groups I, II and III was 78.7%. Further analysis showed that the positive rates for PGI-SO, PGI-I4 and PGI-AE9 were 63.8%, 59.5% and 59.5% respectively and were not significantly different (p greater than 0.05). Comparison between PGI-SO, PGI-I4 and PGI-AE9 activities of Groups I, II and III sera showed no significant differences in any comparison groups except with PGI-AE9 in which Group III sera were more frequently positive than Group II sera (p = 0.004). Follow-up of PGI-SO and PGI-AE9 activities in Group IV patients showed mostly a decrease or no change in the activities of the convalescent sera taken 63 days later. RESA-IFA positive rate in the combined Groups I, II and III sera was 91.7%. There were no significant differences either in the seropositive rates or in the geometric mean antibody titers (GMT) between Groups I, II and III sera. Follow-up in Group IV patients showed no change in antibody titers in 64% of cases, decrease and increase in titers in 29% and 7% of cases respectively. The urease-ELISA seropositive rate in the combined Groups (I, II and III) was 89.5% which is not significantly different from that of RESA-IFA (p greater than 0.05). Comparison between individual Groups (I, II and III) likewise showed no significant differences in both GMT and seropositive rates. Follow-up in Group IV sera showed either no change or a decrease in antibody titers in 55.6% and 44.4% of cases respectively.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2394874480 created "2016-06-24" @default.
• W2394874480 creator A5003991503 @default.
• W2394874480 creator A5008670283 @default.
• W2394874480 creator A5046726895 @default.
• W2394874480 creator A5050475605 @default.
• W2394874480 creator A5055140534 @default.
• W2394874480 creator A5059486789 @default.
• W2394874480 creator A5083681799 @default.
• W2394874480 creator A5084557907 @default.
• W2394874480 date "1989-09-01" @default.
• W2394874480 modified "2023-09-23" @default.
• W2394874480 title "Assessment of putative tests for protective immunity to falciparum malaria." @default.
• W2394874480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2699085" @default.
• W2394874480 hasPublicationYear "1989" @default.
• W2394874480 type Work @default.
• W2394874480 sameAs 2394874480 @default.
• W2394874480 citedByCount "0" @default.
• W2394874480 crossrefType "journal-article" @default.
• W2394874480 hasAuthorship W2394874480A5003991503 @default.
• W2394874480 hasAuthorship W2394874480A5008670283 @default.
• W2394874480 hasAuthorship W2394874480A5046726895 @default.
• W2394874480 hasAuthorship W2394874480A5050475605 @default.
• W2394874480 hasAuthorship W2394874480A5055140534 @default.
• W2394874480 hasAuthorship W2394874480A5059486789 @default.
• W2394874480 hasAuthorship W2394874480A5083681799 @default.
• W2394874480 hasAuthorship W2394874480A5084557907 @default.
• W2394874480 hasConcept C126322002 @default.
• W2394874480 hasConcept C147483822 @default.
• W2394874480 hasConcept C159654299 @default.
• W2394874480 hasConcept C203014093 @default.
• W2394874480 hasConcept C2778048844 @default.
• W2394874480 hasConcept C2778371730 @default.
• W2394874480 hasConcept C2780678043 @default.
• W2394874480 hasConcept C71924100 @default.
• W2394874480 hasConcept C86803240 @default.
• W2394874480 hasConcept C8891405 @default.
• W2394874480 hasConceptScore W2394874480C126322002 @default.
• W2394874480 hasConceptScore W2394874480C147483822 @default.
• W2394874480 hasConceptScore W2394874480C159654299 @default.
• W2394874480 hasConceptScore W2394874480C203014093 @default.
• W2394874480 hasConceptScore W2394874480C2778048844 @default.
• W2394874480 hasConceptScore W2394874480C2778371730 @default.
• W2394874480 hasConceptScore W2394874480C2780678043 @default.
• W2394874480 hasConceptScore W2394874480C71924100 @default.
• W2394874480 hasConceptScore W2394874480C86803240 @default.
• W2394874480 hasConceptScore W2394874480C8891405 @default.
• W2394874480 hasIssue "3" @default.
• W2394874480 hasLocation W23948744801 @default.
• W2394874480 hasOpenAccess W2394874480 @default.
• W2394874480 hasPrimaryLocation W23948744801 @default.
• W2394874480 hasRelatedWork W1966356931 @default.
• W2394874480 hasRelatedWork W1970993918 @default.
• W2394874480 hasRelatedWork W1997856540 @default.
• W2394874480 hasRelatedWork W2014192789 @default.
• W2394874480 hasRelatedWork W2060046542 @default.
• W2394874480 hasRelatedWork W2165065921 @default.
• W2394874480 hasRelatedWork W2220102944 @default.
• W2394874480 hasRelatedWork W4200302535 @default.
• W2394874480 hasRelatedWork W69335772 @default.
• W2394874480 hasRelatedWork W76260333 @default.
• W2394874480 hasVolume "20" @default.
• W2394874480 isParatext "false" @default.
• W2394874480 isRetracted "false" @default.
• W2394874480 magId "2394874480" @default.
• W2394874480 workType "article" @default.